RCS - Solvonis Therapeutic - Appointment of Water Tower Research

Solvonis TherapeuticsAnnouncement

22/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260422:nRSV3912Ba&default-theme=true

RNS Number : 3912B  Solvonis Therapeutics PLC  22 April 2026

 

22 April 2026

Solvonis Therapeutics plc

("Solvonis" or the "Company")

 

 

Appoints Water Tower Research to deepen U.S. market understanding, refine
Company profile and expand institutional investor reach

 

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company
developing novel small-molecule therapeutics for high-burden central nervous
system ("CNS") disorders, is pleased to announce the appointment of Water
Tower Research LLC ("Water Tower Research" or "WTR") to support the Company in
three areas of increasing importance: deepening its understanding of the
evolving U.S. market environment, refining its corporate profile in that
market, and broadening intuitional investor reach.

Water Tower Research ("WTR") is a U.S.-based research and investor engagement
firm. Under the engagement, WTR is expected to provide research coverage,
supporting content and broader market-facing support. The agreed scope
includes initiation of coverage reports, update notes, management series
reports, fireside chats, podcasts and other research content. Content
distribution is expected to take place through WTR's network, including
research aggregators, its website, direct channels and social media, with
research and events available for investor access via the firm's website and
other distribution channels.

First, Solvonis believes the appointment will help deepen the Company's
understanding of the evolving U.S. market environment. Recent developments in
the United States have underlined the importance of regulatory, policy and
capital-markets momentum in CNS and neuropsychiatry, and the Company believes
that understanding this backdrop is increasingly important as it advances its
pipeline.

Second, the appointment is expected to help refine the Company's profile in a
market that is highly relevant to key programmes across the Solvonis pipeline,
including SVN-002, its U.S.-focused programme in moderate-to-severe alcohol
use disorder, SVN-015, its stimulant addiction programme, which has been
accepted into the U.S. National Institute on Drug Abuse's Addiction Treatment
Discovery Program, and SVN-114, its lead PTSD candidate.

Third, Solvonis believes the appointment will help expand the Company's
institutional investor reach in the U.S. The United States remains the most
important capital-markets arena for innovative CNS companies, and broader
access to U.S. institutional investors is regarded as an important step in
strengthening the Solvonis equity story.

Solvonis also believes there remains a substantial valuation gap between the
Company and comparable U.S.-listed CNS peers. In that context, improving U.S.
market understanding, sharpening the Company's profile and broadening investor
reach are all regarded as worthwhile steps in supporting the Company's
longer-term market positioning.

Anthony Tennyson, Chief Executive Officer of Solvonis, said: "Solvonis
believes this appointment is an important and practical step in strengthening
its position in the United States.

The U.S. is highly relevant both to key programmes across the pipeline and to
the Company's longer-term capital-markets ambition. Water Tower Research
brings an established platform to help Solvonis better understand that market,
refine its profile, and broaden investor reach."

 

Enquiries:

 

 Solvonis Therapeutics plc                                       Via Walbrook
 Anthony Tennyson, CEO & Executive Director

 Singer Capital Markets (Broker)                                 +44 (0) 20 7496 3000
 Phil Davies

 Walbrook PR (PR/IR advisers)  Tel: +44 (0)20 7933 8780 or solvonistherapeutics@walbrookpr.com
                               (mailto:solvonistherapeutics@walbrookpr.com)
 Anna Dunphy                                                     Mob: +44 (0)7876 741 001
 Lianne Applegarth                                               Mob: +44 (0)7584 391 303
 Rachel Broad                                                    Mob: +44 (0)7747 515 393

 

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company
developing small-molecule therapeutics for high-burden central nervous system
(CNS) disorders. Headquartered in London and listed on the main market of the
London Stock Exchange, Solvonis is advancing a differentiated pipeline of
repurposed and discovery-stage compounds across addiction and psychiatry.

 

The Company's lead programmes target Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD), with additional development and
discovery work supporting expansion into further addiction and psychiatric
indications, including stimulant use disorder and depressive disorders.

 

Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK,
while SVN-002 is preparing for a Phase 2b trial in the United States targeting
moderate-to-severe AUD. The Company's PTSD discovery programme has identified
SVN-114 as a lead compound, emerging from a proprietary compound series
designed to modulate key brain signalling systems associated with emotional
processing and social behaviour.

 

In parallel, Solvonis is advancing proprietary CNS discovery programmes
supported by a dedicated compound library to identify new small-molecule
modulators of key neurotransmitter systems. This platform enables efficient
early-stage innovation and supports the Company's integrated approach to
developing therapies across addiction and psychiatry.

 

With a capital-efficient development model and a focus on partnering
opportunities, Solvonis aims to deliver sustained value through innovation in
CNS therapeutics.

 

solvonis.com (https://solvonis.com) | X (Twitter) (https://x.com/Solvonis)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADBGDSSUDDGLB



            Copyright 2019 Regulatory News Service, all rights reserved